Crossmark

Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?

Crossref DOI link: https://doi.org/10.1007/s40265-018-1011-6

Published Online: 2018-11-22

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sockel, Katja

Platzbecker, Uwe
License Information

Text and Data Mining valid from 2018-11-22
More Information

Article History

First Online: 22 November 2018

Compliance with Ethical Standards

:

: No external funding was used in the preparation of this article.

: Katja Sockel and Uwe Platzbecker have no conflicts of interest that are directly relevant to the contents of this article.